Obios

Obios is redefining obesity treatment with our data-driven prescription system based on the Drinkometer, a medical device, and our software. Targeting the $100B anti-obesity medication market, we enhance prescription precision, moving away from the current trial and error approach. Our Drinkometer tracks ingestive behavior, the only biomarker directly associated with anti-obesity medications outcome. Our software leverages these insights allowing tailored treatment. This research-based approach enables doctors to make informed prescriptions, improving patient outcomes, cutting healthcare costs and streamlining drug production. With 50 ready to buy opinion leaders and strategic pharmaceutical partnerships, Obios is advancing to set a new benchmark in anti-obesity medication prescription.